Advertisement

Pharmacy World and Science

, Volume 19, Issue 3, pp 119–125 | Cite as

Etoposide phosphate, the water soluble prodrug of etoposide

  • H.J. Guchelaar
  • A. Vermes
  • I. Vermes
  • C. Haanen
Article

Abstract

Apoptosis, or programmed cell death, is an orderly and genetically controlled form of cell death. In a morphological sense, it differs from necrosis in that cellular shrinkage and chromatin condensation occurs, followed by fragmentation of nuclear components within membrane-bound vesicles which are cleared by phagocytosis without damage to adjacent tissue. The molecular pathway includes an initiating phase, which starts after signalling by external triggers, such as ligation to distinct receptors or by endogenous mechanisms related to aging or to exogenous irreversible cellular or nuclear damage. The initiation phase is followed by a decision phase. During this phase transduction occurs of the apoptotic signal to nuclear and cytoplasmatic target enzymes, which includes activation of endonucleases and enzymatic alterations of the cytoskeleton. There are numerous proteins and lipid–derived moieties which modulate the apoptotic mechanism in positive or negative direction. The execution phase is started when the cell has arrived at a stage of no return. The nuclear DNA is cleaved into multiples of 180–200 basepairs, the plasma membrane integrity and the mitochondria remain initially intact, the cell splits up into apoptotic bodies, small vesicles which enclose the nuclear and cellular remnants. Finally, the clearing phase is arrived, when the apoptotic bodies are phagocytosed by adjacent cells and macrophages. It is thought that the pharmacodynamics of anticancer drugs consists of two distinct steps. The first step includes the interaction with its cellular target, which is not lethal per se. The commitment of the cell to undergo apoptosis forms the second step. The efficacy of anticancer drugs is determined by the ability to selectively sensitize tumor cells to apoptosis, which depends to a large extent from the expression of various oncogenes, such as bcl–2, p53, bax, ras, c–myc and others, and from endogenous factors. It is a challenge in pharmacological research to explore apoptosis by modulating the extrinsic and intrinsic regulators in a positive or negative direction in order to improve the efficacy of anticancer treatment.

Apoptosis Chemotherapy Drug resistence Necrosis P53 tumor suppressor gene Programmed cell death 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kerr JFR. Shrinkage necrosis: a distinct mode of cellular death.J Pathol 1971;105:13-20.Google Scholar
  2. 2.
    Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.Google Scholar
  3. 3.
    Wyllie AH. Glucocorticoid-induced thymocyte apoptosis isassociated with endogenous endonuclease activation. Nature 1980;284:555-6.Google Scholar
  4. 4.
    Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of celldeath. Annu Rev Cell Biol 1991;7:663-98.Google Scholar
  5. 5.
    Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990;68:1071-4.Google Scholar
  6. 6.
    Bursch W, Paffe S, Putz B, Barthel G, Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci in rats. Carcinogenesis 1990;11:847-53.Google Scholar
  7. 7.
    Cohen JJ. Apoptosis. Immunol Today 1993;14:126-30.Google Scholar
  8. 8.
    Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.Google Scholar
  9. 9.
    Reed JC. Minireview: cellular mechanisms of disease series. Bcl-2 and the regulation of programmed cell death. J Cell Biol1994;124:1-6.Google Scholar
  10. 10.
    Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science1989;245:301-5.Google Scholar
  11. 11.
    Yonehara S, Ishii A, Yonehara M. A cell killing monoclonal antibody (anti-FAS) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med1989;169:1747-56.Google Scholar
  12. 12.
    Di Virgilio. The P 2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today1995;16:524-8.Google Scholar
  13. 13.
    Ferguson DJP, Anderson TJ. Ultrastructural observations on cell death by apoptosis in the ‘resting’ human breast. Virchows Arch 1981;393:193-203.Google Scholar
  14. 14.
    Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flowcytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995;184:39-51.Google Scholar
  15. 15.
    Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995;20:73-7.Google Scholar
  16. 16.
    Obeid LM, Hannun YA. Ceramide: A stress signal and mediator of growth suppression and apoptosis. J Cell Biochem1995;58:191-8.Google Scholar
  17. 17.
    Pushkareva M, Obeid LM, Hannun YA. Ceramide: an endoge-nous regulator of apoptosis and growth suppression. Immunol Today 1995;16:294-7.Google Scholar
  18. 18.
    Green DR, Martin SJ. The killer and the executioner: howapoptosis controls malignancy. Curr Opin Immunol 1995;7:694-703.Google Scholar
  19. 19.
    Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS, Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3.Google Scholar
  20. 20.
    Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 1994;371:519-23.Google Scholar
  21. 21.
    Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. FEBS Lett 1996;378:107-10.Google Scholar
  22. 22.
    Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.Google Scholar
  23. 23.
    Craig RW. The BCL-2 gene family. Cancer Biol 1995;6:35-43.Google Scholar
  24. 24.
    White E. Life, death, and the pursuit of apoptosis. Genes Developm 1996;10:1-15.Google Scholar
  25. 25.
    Tsujimoto Y, Gorham J, Coosman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3.Google Scholar
  26. 26.
    Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer S. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.Google Scholar
  27. 27.
    Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax that accelerates programmed cell death. Cell 1993;74:609-19.Google Scholar
  28. 28.
    Nunez G, Merino R, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994;15:582-8.Google Scholar
  29. 29.
    Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995;13:513-43.Google Scholar
  30. 30.
    Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sc1995;20:198-202.Google Scholar
  31. 31.
    Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer and Metast Rev 1995;14:149-61.Google Scholar
  32. 32.
    Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-26.Google Scholar
  33. 33.
    Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.Google Scholar
  34. 34.
    Carson DA. Cancer progression and p53. Lancet 1995;346:1009-11.Google Scholar
  35. 35.
    Lane DP. P53, guardian of the genome. Nature 1992;358:15-16.Google Scholar
  36. 36.
    Fésüs L, Szondy Z, Uray I. Probing the molecular program of apoptosis by cancer chemopreventive agents. J Cell Biochem 1995;22(suppl):151-61.Google Scholar
  37. 37.
    Martin SJ, Green DR. Protease activation during apoptosis; death by thousand cuts? Cell 1995;82:345-52.Google Scholar
  38. 38.
    Cohen JJ, Duke RC. Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132:138-42.Google Scholar
  39. 39.
    Cohen JJ, Duke RC, Chervenak R, Sellins KS, Olson LK. DNA fragmentation in targets of CTL: an example of programmed cell death in the immune system. Adv Exp Med Biol 1985;184:493-508.Google Scholar
  40. 40.
    Murgia M, Pizzo P, Sandona D, Zanovello P, Rizzuto R, Di Virgilio F. Mitochondrial DNA is not fragmented during apoptosis. J Biol Chem 1992;267:1039-41.Google Scholar
  41. 41.
    McConkey DJ, Hartzell P, Nicotera P, Orrenius S. Calcium activated DNA fragmentation kills immature thymocytes. FASEB J 1989;3:1843-9.Google Scholar
  42. 42.
    Zheng LM, Zychilinsky A, Liu CC, Ojcius DM, Young JDE. Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 1991;112:279-88.Google Scholar
  43. 43.
    Jacobson MD, Burne JF, Raff MC. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 1994;13:1899-910.Google Scholar
  44. 44.
    Schulze-Osthoff K, Walczak H, Droge W, Krammer PH. Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol 1994;127:15-20.Google Scholar
  45. 45.
    Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J Cell Biol 1993;123:7-22.Google Scholar
  46. 46.
    Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994;79:353-64.Google Scholar
  47. 47.
    Morris RG, Hargreaves AD, Duval E, Wyllie AH. Hormoneinduced death. II. Surface changes in thymocytes undergoing apoptosis. Am J Pathol 1984;115:426-31.Google Scholar
  48. 48.
    Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel ‘chargesensitive’ recognition mechanism. J Clin Invest 1989;84: 1518-27.Google Scholar
  49. 49.
    Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cell undergoing apoptosis. Immunology Today1993;14:131-6.Google Scholar
  50. 50.
    Savill JS, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990;343:170-3.Google Scholar
  51. 51.
    Savill JS, Wyllie AH, Henson JE, Walport MJ Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989;83:865-75.Google Scholar
  52. 52.
    Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Cambell PA, Henson PM. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol 1992;149:4029-35.Google Scholar
  53. 53.
    Fadok VA, Laszlo DJ, Noble PW, Weinstein L, Riches DWH, Henson PM. Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol 1993;151:4274-85.Google Scholar
  54. 54.
    Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognation and removal by macrophages. J Immunol 1992;148:2207-16.Google Scholar
  55. 55.
    Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, van Schie RCAA, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.Google Scholar
  56. 56.
    Hall SE, Savill JS, Henson PM, Haslett C. Apoptotic neutrophils are phagocytosed by fibroblast with participation of the fibroblast vitronectin receptor and involvement of a mannose/fucose-specific lectin. J Immunol 1994;153:3218-27.Google Scholar
  57. 57.
    Flora PK, Gregory CD. Recognition of apoptotic cells by human macrophages: inhibition by a monocyte/macrophage-specific monoclonal antibody. Eur J Immunol 1994;24:2625-32.Google Scholar
  58. 58.
    Bright JJ, Khar A. Apoptosis: programmed cell death in health and disease. Bioscience Rep 1994;14:67-81.Google Scholar
  59. 59.
    Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.Google Scholar
  60. 60.
    Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.Google Scholar
  61. 61.
    Törmänen U, Eerola AK, Rainio P, Vähäkangas K, Soini Y, Sormunen R, Bloign R, Lehto VP, Pääkkö R. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595-602.Google Scholar
  62. 62.
    Borg A, Lennerstrand J, Stenmark-Askmalm M, Fernö M, Brisfors A, Öhrvik A, Stal O, Killander D, Lane D, Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995;71:1013-17.Google Scholar
  63. 63.
    Binder C, Marx D, Binder L, Schauer A, Hiddeman W. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 1996;7:129-33.Google Scholar
  64. 64.
    Hellemans P, Dam van PA, Weyler J, Oosterom van AT, Buytaert P, Marck van E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.Google Scholar
  65. 65.
    Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.Google Scholar
  66. 66.
    Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.Google Scholar
  67. 67.
    Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs 1994;5:3-9.Google Scholar
  68. 68.
    Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Path 1994;144:1045-66.Google Scholar
  69. 69.
    Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anti-Cancer Drugs 1995;6:443-50.Google Scholar
  70. 70.
    Guchelaar H-J, Vermes I, Kalsbeek-Batenburg E, Haanen C. A novel flowcytometric assay allows in vitro assessment of the apoptosis-and necrosis inductive potential of anticancer drugs and combined treatment. Proc Am Soc Clin Oncol 1996;89 (abstract 23).Google Scholar
  71. 71.
    Gruber J, Greil R. Apoptosis and therapy of malignant diseases of the hemotopoietic system. Int Arch Allergy Immunol 1994;105:368-73.Google Scholar
  72. 72.
    Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181-8.Google Scholar
  73. 73.
    Sen S, D'Incalci M. Biochemical events and relevance to cancer chemotherapy. FEBS 1992;307:122-7.Google Scholar
  74. 74.
    Zinzani PL, Tosi P, Visani G, Martinelli G, Farabegoli P, Buzzi M, Ottaviani E, Salvucci M, Bendandi M, Zaccaria A, Tura S. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia celss. Am J Hematol 1994;47:301-6.Google Scholar
  75. 75.
    Hutschtscha LI, Bartier WA, Malmstrom A, Tattersall MHN. Cell death by apoptosis following anticancer drug treatment in vitro. Int J Oncol 1995;6:585-93.Google Scholar
  76. 76.
    Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-62.Google Scholar
  77. 77.
    Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32a:921-6.Google Scholar
  78. 78.
    Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989;49:5870-8.Google Scholar
  79. 79.
    Meyn RE, Stephens LC, Hunter NR, Milas L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994;33:410-4.Google Scholar
  80. 80.
    Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR, Darzynkiewicz Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemia. Leukemia 1993;7:659-70.Google Scholar
  81. 81.
    Idink CAM, Schaafsma MR, Vermes I, Guchelaar HJ, Kalsbeek E, Richel DJ. 2-Chlorodeoxyadenosine (2-CDA) induced apoptosis in patients with hairy cell leukemia. Proc Am Soc Clin Oncol 1996;89 (abstract 24).Google Scholar
  82. 82.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, OwenSchaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54;2287-91.Google Scholar
  83. 83.
    Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.Google Scholar
  84. 84.
    Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. P53 status and the efficacy of cancer therapy in vivo. Science 1994;266:805-10.Google Scholar
  85. 85.
    Evans DL, Tilby M, Dive C. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of levels of drug accumulation and DNA adduct formation. Cancer Res 1994;54:1596-603.Google Scholar
  86. 86.
    D'Amico AV, McKenna WG. Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother and Oncol 1994;33:3-10.Google Scholar
  87. 87.
    Malcomson RDG, Oren M, Wyllie AH, Harrison DJ. P53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 1995;72:952-7.Google Scholar
  88. 88.
    Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, Mueller H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.Google Scholar
  89. 89.
    Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-8.Google Scholar
  90. 90.
    Aldridge DR, Arends MJ, Radford IR. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival doeseresponse. Br J Cancer 1995;71:571-7.Google Scholar
  91. 91.
    Dheln J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.Google Scholar
  92. 92.
    Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.Google Scholar
  93. 93.
    Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol/Hematol 1995;18:137-53.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • H.J. Guchelaar
    • 1
  • A. Vermes
    • 1
  • I. Vermes
    • 1
  • C. Haanen
    • 1
  1. 1.Department of Clinical Pharmacy,Academic Medical Center, University of Amsterdam, Meibergdreef 9,Amsterdam,The Netherlands

Personalised recommendations